Social Cost of Blindness Due to AMD and Diabetic Retinopathy in the United States in 2020

被引:22
作者
Moshfeghi, Andrew A. [1 ]
Lanitis, Tereza [2 ]
Kropat, Georg [2 ]
Kuznik, Andreas [3 ]
Gibson, Andrea [3 ]
Feng, Haidong [4 ]
Prenner, Jonathan [5 ]
机构
[1] Univ Southern Calif, Keck Sch Med, Roski Eye Inst, Dept Ophthalmol, Los Angeles, CA 90007 USA
[2] Evidera, London, England
[3] Regeneron Pharmaceut, Tarrytown, NY USA
[4] Evidera, Waltham, MA USA
[5] Rutgers Robert Wood Johnson Med Sch, Dept Ophthalmol, 10 Plum St, New Brunswick, NJ 08901 USA
关键词
VISUAL IMPAIRMENT; MACULAR DEGENERATION; INTRAVITREAL AFLIBERCEPT; PANRETINAL PHOTOCOAGULATION; GLOBAL CAUSES; VISION LOSS; DEVICE USE; AGE; IMPACT; INDIVIDUALS;
D O I
10.3928/23258160-20200401-01
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
BACKGROUND AND OBJECTIVE: To estimate the social cost of blindness due to wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR) in the United Stales in 2020. PATIENTS AND METHODS: Excess costs that occur because of blindness were estimated as the difference in costs in blind versus non-blind individuals. Per-patient costs were aggregated using the number of cases of blindness due to wAMD, DME, and PDR projected in 2020. RESULTS: Associated annual excess direct costs, indirect costs, and quality-adjusted life year loss per blind individual were $4,944, $54,614, and 0.214, respectively. Combining estimates with 246,423 projected cases of blindness due to wAMD, DME, and PDR translated to total societal costs of $20 billion in 2020, estimated to triple by 2050. CONCLUSION: Excess social costs associated with blindness in individuals with wAMD, DME, and PDR are substantial, with more than half of the burden attributed to indirect costs.
引用
收藏
页码:S6 / +
页数:21
相关论文
共 49 条
  • [1] American Foundation for the Blind, 2017, FIN CONS STAT FINAN
  • [2] [Anonymous], COST VISION PROBLEMS
  • [3] Arias E, 2017, NATL VITAL STAT REPO, V66
  • [4] BrightFocus Foundation, AG REL MAC DEG FACTS
  • [5] The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
    Brown G.C.
    Brown M.M.
    Lieske H.B.
    Turpcu A.
    Rajput Y.
    [J]. International Journal of Retina and Vitreous, 3 (1)
  • [6] Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
  • [7] Bureau of Labor Statistics, 2017, NAT OCC EMPL MENT WA
  • [8] Bureau of Labor Statistics, 2017, NAT OCC EMPL WAG EST
  • [9] Estimates of Incidence and Prevalence of Visual Impairment, Low Vision, and Blindness in the United States
    Chan, Tiffany
    Friedman, David S.
    Bradley, Chris
    Massof, Robert
    [J]. JAMA OPHTHALMOLOGY, 2018, 136 (01) : 12 - 19
  • [10] Ranibizumab for the treatment of wet AMD: a summary of real-world studies
    Chong, V.
    [J]. EYE, 2016, 30 (02) : 270 - 286